PGD2 causes hair loss according to Dr. Cotsarelis

[Scoots]

I've been wondering, since Cotsarelis is heading up Follica, and that treatment (from what we know) doesn't target PGD2, how does that affect the chances of Follica being released? We obviously don't know anything about their phase 2 results or if they're even planning for phase 3. But do you think this recent discovery negates Follica's method as to what sparks regrowth of hair?

You would think Cotsarelis would be promoting his own product, yet in the interview video posted earlier in this thread he instead suggests that an effective MPB treatment could come from the PGD2 blocking drugs currently in clinical trials.

[Pate]

I've been wondering, since Cotsarelis is heading up Follica, and that treatment (from what we know) doesn't target PGD2, how does that affect the chances of Follica being released? We obviously don't know anything about their phase 2 results or if they're even planning for phase 3. But do you think this recent discovery negates Follica's method as to what sparks regrowth of hair?

It doesn't negate Follica's other research, which we don't know much about because it's kept tightly under wraps but seems to involve wounding and lithium carbonate, a drug for bipolar disorder.

But to be honest I don't expect much from Follica. They seem to be making only a half-hearted effort towards commercialising their work and Cotsarelis seems to be more interested in the research than the practice. This is why some guys here get on his case, but I don't see the problem with it. He's making some good discoveries, it's just the ungrateful pr*cks on this board who seem to think he was put on this earth to fix their own personal hair loss.

You would think Cotsarelis would be promoting his own product, yet in the interview video posted earlier in this thread he instead suggests that an effective MPB treatment could come from the PGD2 blocking drugs currently in clinical trials.

If you read some of the earlier stuff on this thread you will see that several of the guys involved in the study with Cotsarelis work for companies that have patents over those PGD2 blocking drugs. So it's not Cotsarelis personally who's benefitting but several of the other study authors are.